The most appropriate treatment for localized prostatic cancer remains controversial: which tumors should be treated? And what is the respective place of radical prostatectomy versus radiotherapy. The results obtained with these two treatment modalities reported by various american centers are compared for their ability to control local disease. In the absence of any decisive therapeutic trial, the data suggest that radical prostatectomy represents a valuable therapeutic approach in selected cases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of Imaging and Pharmacological Treatment Strategies in Refractory Ventricular Tachycardia in Critically Ill Patients: A Systematic Review.
Cureus
December 2024
Medicine, Universidad Santiago de Cali, Cali, COL.
Ventricular tachycardia (VT) is a life-threatening arrhythmia often leading to sudden cardiac death, particularly in critically ill patients. Refractory VT, characterized by recurrent episodes requiring intervention, poses unique challenges for management, necessitating advanced diagnostic and therapeutic strategies. This systematic review evaluates the impact of imaging and pharmacological treatments in managing refractory VT in critically ill patients.
View Article and Find Full Text PDFLong-term outcomes of LDR-brachytherapy for localized prostate cancer.
Front Oncol
January 2025
Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Introduction: This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.
Materials And Methods: 235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated.
How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?
BMJ Oncol
November 2023
Rowett Institute, University of Aberdeen, Aberdeen, UK.
Cancer remains one of the leading causes of death worldwide, despite advances in treatments such as surgery, chemotherapy, radiotherapy and immunotherapy. The role of the gut microbiota in human health and disease, particularly in relation to cancer incidence and treatment response, has gained increasing attention. Emerging evidence suggests that dietary fibre, including prebiotics, can modulate the gut microbiota and influence antitumour effects.
View Article and Find Full Text PDFCardiovascular health: an important component of cancer survivorship.
BMJ Oncol
October 2023
MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK.
Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals free of the disease following treatment. Epidemiological studies demonstrate that cancer survivors are at an increased risk of cardiovascular disease (CVD), with cardiovascular (CV) mortality overtaking cancer mortality in some tumour types.
View Article and Find Full Text PDFBenefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New Zealand.
BMJ Oncol
December 2023
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Objectives: Non-mortality benefits of breast cancer screening are rarely considered in assessments of benefits versus harms. This study aims to estimate the rate of overdiagnosis in women with screen-detected breast cancer (SDBC) by allocating cases to either possibly overdiagnosed (POD) or not overdiagnosed categories and to compare treatment recommendations for surgery and adjuvant treatments by category, age at diagnosis and cancer stage.
Methods And Analysis: Retrospective secondary analysis of 10 191 women diagnosed with breast cancer in Australia and New Zealand in 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!